Form 4: Ginkgo Bioworks CFO Mark Dmytruk Reports Stock Transactions

Ginkgo Bioworks CFO Mark Dmytruk executed multiple transactions involving Class A Common Stock and Restricted Stock Units, including vesting and sales to cover tax obligations.

Summary

• Mark Dmytruk, the Chief Financial Officer of Ginkgo Bioworks Holdings, Inc., reported several transactions involving the company's Class A Common Stock and Restricted Stock Units (RSUs).
• On January 3, 2025, Dmytruk acquired 450, 453, and 572 shares of Class A Common Stock through the vesting of RSUs.
• Following these acquisitions, Dmytruk's direct holdings increased to 33,861 shares.
• On January 6, 2025, Dmytruk sold 645 shares of Class A Common Stock at a price of $11.718 per share.
• These sales were to cover tax withholding obligations related to the vesting of RSUs and do not represent discretionary trades.
• The RSUs vest in 48 equal monthly installments, with some beginning on April 1, 2023, and others on April 1, 2024.

Sentiment

Score: 6

Explanation: The document reflects routine insider transactions related to equity compensation. While the sale of shares could be seen as slightly negative, it is a standard practice for tax obligations, so the overall sentiment is neutral.

Positives

• The vesting of RSUs indicates that Dmytruk is meeting the conditions of his equity compensation plan.
• The company's equity incentive plans allow for 'sell to cover' transactions, which is a common practice for managing tax obligations.

Negatives

• The sale of shares, even for tax purposes, could be perceived negatively by some investors, although it is a standard practice.

Risks

• While the sales are for tax obligations, large volumes of such sales by insiders could potentially create downward pressure on the stock price.
• Changes in tax laws could impact the way these transactions are handled in the future.

Management Comments

• The sales to cover tax withholding obligations do not represent discretionary trades by the Reporting Person.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders execute transactions in their company's stock. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• The vesting schedule of 48 months for RSUs is a common practice in the tech and biotech industries.
• The 'sell to cover' mechanism for tax obligations is also a standard practice among publicly traded companies, including those like Moderna and BioNTech, which also have significant equity compensation programs.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they are related to standard equity compensation practices.
• The sales to cover tax obligations could have a slight downward pressure on the stock price, but this is likely to be minimal.

Key Dates

Keywords

Ginkgo Bioworks, insider trading, Form 4, stock transactions, restricted stock units, RSU, equity compensation, tax withholding, CFO, Mark Dmytruk